Network pharmacology and in vitro experiments reveal sophoridine‐induced apoptosis and G₁ phase arrest via ROS‐dependent PI3K/Akt/FoxO3a pathway activation in human bladder cancer cells.

Bladder cancer (BLCA), a common primary malignancy, exhibits resistance to conventional chemotherapeutic agents. Sophoridine (SR) is a quinoline alkaloid derived from the traditional Chinese herb Sophora alopecuroides L., which belongs to the legume family Sophoraceae. SR is reported to exert growth‐inhibitory effects against several cancers. However, the mechanisms underlying the growth‐inhibitory effects of SR on BLCA have not been elucidated. This study performed molecular and cellular experiments to verify the growth‐inhibitory effects of SR on BLCA and the underlying mechanisms. SR inhibited cell proliferation and promoted apoptosis and G1‐phase arrest through the PI3K/AKT/FoxO3a signaling pathway. More interestingly, the effects of SR can be attributed to the accumulation of reactive oxygen species (ROS) in vivo. ROS may be the upstream factor of this pathway. Additionally, SR inhibited the migration and invasion of BLCA cells in a concentration‐dependent or time‐dependent manner. This is the first study to demonstrate the ROS‐dependent PI3K/AKT/FoxO3a pathway‐mediated anticancer effect of SR and the anticancer mechanism of SR in BLCA. The correlation between SR‐induced ROS‐dependent cell proliferation inhibition, apoptosis, cell cycle arrest, and PI3K/AKT/FoxO3a suggests that SR is a promising novel therapeutic for BLCA. [ABSTRACT FROM AUTHOR]